Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2023 Nov;30(6):872-884.
doi: 10.1007/s12282-023-01505-x. Epub 2023 Oct 7.

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

Mitsuo Terada  1 , Aki Ito  2 , Yuichiro Kikawa  3 , Kei Koizumi  4 , Yoichi Naito  5 , Tatsunori Shimoi  6 , Mikiya Ishihara  7 , Takashi Yamanaka  8 , Yukinori Ozaki  9 , Fumikata Hara  9 , Rikiya Nakamura  10 , Masaya Hattori  11 , Minoru Miyashita  12 , Naoto Kondo  13 , Tetsuhiro Yoshinami  14 , Masahiro Takada  15 , Koji Matsumoto  16 , Kazukata Narui  17 , Shinsuke Sasada  18 , Takayuki Iwamoto  19 , Mitsuchika Hosoda  20 , Yuko Takano  21 , Takaaki Oba  22 , Hitomi Sakai  23 , Akari Murakami  24 , Toru Higuchi  25 , Junko Tsuchida  26 , Yuko Tanabe  27 , Tomoko Shigechi  28 , Emi Tokuda  29 , Michiko Harao  30 , Shinichiro Kashiwagi  31 , Junichi Mase  32 , Junichiro Watanabe  33 , Shigenori E Nagai  34 , Chikako Yamauchi  35 , Yutaka Yamamoto  36 , Hiroji Iwata  11 , Shigehira Saji  29 , Tatsuya Toyama  1
Affiliations
Practice Guideline

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

Mitsuo Terada et al. Breast Cancer. 2023 Nov.

Abstract

The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines consist of 12 background questions (BQs), 33 clinical questions (CQs), and 20 future research questions (FRQs). Multiple outcomes including efficacy and safety were selected in each CQ, and then quantitative and qualitative systematic reviews were conducted to determine the strength of evidence and strength of recommendation, which was finally determined through a voting process among designated committee members. Here, we describe eight selected CQs as important updates from the previous guidelines, including novel practice-changing updates, and recommendations based on evidence that has emerged specifically from Japanese clinical trials.

Keywords: Breast cancer; Guidelines; JBCS; Systemic treatment.

PubMed Disclaimer

Conflict of interest statement

M. Terada and A. Ito have no conflict of interest. YK received honoraria from AstraZeneca, Novartis, Pfizer, Eisai, Chugai, and Daiichi Sankyo, and participated on a Data Safety Monitoring Board or Advisory Board of Daiichi Sankyo. KK received honoraria from Pfizer and Chugai. YN received research funding from ABBVIE, Ono, Daiichi Sankyo, Taiho, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai, and Bayer, and payment or honoraria from AstraZeneca, Eisai, Ono, Gardant, Takeda, Eli Lilly, Novartis, Pfizer, Chugai, PDR pharma, Nihon Kayaku, Taiho, Bristol, Bayer, Daiichi Sankyo, and MSD. MI received honoraria from Chugai, Eisai, MSD, Ono, Daiichi-Sankyo, Otsuka, and Eli Lilly. TY received honoraria from AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa-Kirin, Novartis, Pfizer and Taiho. YO received honoraria from Daiichi Sankyo, Pfizer, Kyowa Kirin, and Chugai Pharma. FH received honoraria from Pfizer, Kyowa Kirin, Eli Lilly, Chugai, Daiichi Sankyo, and Taiho. RN received honoraria from Chugai, AstraZeneca, Eli Lilly, Novartis, and Daiichi Sankyo. MH received honoraria from Eli Lilly, and Daiichi Sankyo. TY received honoraria from Pfizer, Chugai, MSD, Eli Lilly, AstraZeneca and Eisai. MT received research funding from Daiichi Sankyo, AstraZeneca, KBCRN, JBCRG, ABCSG, Yakult, Medbis and IQVIA Services Japan and received honoraria from Daiichi Sankyo, AstraZeneca, Chugai, Eli Lilly, Pfizer, Taiho, Eisai, and MSD. MK received Research funding from Daiichi Sankyo, MSD, Eli Lilly, and Gilead Sciences, received honoraria from MSD, Kyowa Kirin, and Chugai. KN received honoraria from Pfizer, Lilly, Daiichi-Sankyo, Eisai, and Chugai. TI received research funding from Pfizer, and received honoraria from Kyowa Kirin, Chugai, Exact Sciences, Takeda, Daiichi Sankyo, and AstraZeneca. MH received honoraria from Eli Lilly. HS received research funding from Eisai, and received honoraria from Daiichi Sankyo and Eli Lilly. AM received honoraria from Daiichi Sankyo, Chugai, Eli Lilly, and Pfizer, and participated on a Data Safety Monitoring Board or Advisory Board of Daiichi Sankyo. YT received research funding from Daiichi Sankyo, Eli Lilly, MSD, Taiho, and Ono. SK received honoraria from Eisai, Chugai, and Eli Lilly. JW received honoraria from Chugai, Eisai, Pfizer, Daiichi Sankyo, and Eli Lilly. SN received honoraria from Eli Lilly, Pfizer, Chugai, Taiho, Eisai, MSD, Daiichi Sankyo, and AstraZeneca. YY received research funding from Chugai, Kyowa-Kirin, Eisai, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Takeda, Eli Lilly, Pfizer, and Novartis, received honoraria from AstraZeneca, Chugai, Kyowa-Kirin, Novartis, Eli Lilly, Pfizer, Daiichi-Sankyo, Nippon-Kayaku, Taiho, Eisai, Takeda, MSD, Sysmex, and Exact Science, participated on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Chugai, Novartis, MSD, Eli Lilly, Pfizer, and Daiichi-Sankyo, and is a member of the Board of Director of Japanese Breast Cancer Society and Japan Breast Cancer Research Group. HI received grants from Chugai, Daiichi Sankyo, and AstraZeneca, consulting fees from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, and Giliead, and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. SS received research funding from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo, received honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nippon Kayaku, participated on a Data Safety Monitoring Board or Advisory Board of Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD, is an executive member of JBCRG, JBCS, JSMO, and BIG. TT received research funding from Chugai and Eisai, and received honoraria from Eli Lilly, MSD, Pfizer, Daiichi-Sankyo, and Chugai.

References

    1. Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:322–331. doi: 10.1007/s12282-020-01085-0. - DOI - PMC - PubMed
    1. Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:4–8. doi: 10.1007/s12282-019-01030-w. - DOI - PMC - PubMed
    1. Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, et al. The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:9–16. doi: 10.1007/s12282-019-01019-5. - DOI - PMC - PubMed
    1. Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 Edition. Breast Cancer. 2020;27:17–24. doi: 10.1007/s12282-019-01025-7. - DOI - PMC - PubMed
    1. Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:74–84. doi: 10.1016/S1470-2045(20)30534-9. - DOI - PubMed

Publication types

LinkOut - more resources